Novo Nordisk registers Phase 3 cagrilintide trial; Penn semaglutide study posts results

Two items moved this week for Novo Nordisk's obesity portfolio, one a new registered trial and one a completed study with results now posted.

• Novo Nordisk's Phase 3 trial "RENEW 4" (NCT07745504) is recruiting participants to compare two device presentations of cagrilintide against placebo in people with overweight or obesity. The trial plans to enroll 285 participants.¹ The primary outcome is relative change in body weight from baseline to week 26, measured as a percentage.¹
• A Phase 4 study led by the University of Pennsylvania with Novo Nordisk as collaborator, "STABLE Wt Loss" (NCT05548647), has completed and posted results on semaglutide's long-term effects on appetite and eating behavior. The trial randomized 120 subjects with a BMI of at least 30 kg/m2, or at least 27 kg/m2 with one or more obesity-related comorbidities, to 60 weeks of semaglutide 2.4 mg or placebo alongside lifestyle intervention.² The primary aim was to compare semaglutide's effect against placebo on ad libitum energy intake during a lunch meal at weeks 20, 40, and 60.²